The implementation of antibody-based therapy against IL-13 (Anti-IL-13) in treating PF revealed that a potent candidate, tralokinumab, reduced matrix accumulation, lung apoptosis, and lung fibrosis. The gene discussed is IL13; the disease is pemphigus foliaceus.